AI Article Synopsis
Article Abstract
Chronic lymphocytic leukaemia (CLL) with increased prolymphocytes (CLL/PL) has been defined by the World Health Organization (WHO) classification and considered as a progressive and clinically aggressive variant of CLL. To further characterize the biological features of this disease, we performed IgVH gene mutational status, FISH and high-resolution comparative genomic hybridization (HR-CGH) analysis in 17 cases of CLL/PL. All CLL/PL utilized members of VH1, VH3 and VH4 families, with the highest prevalence of the VH1-69 gene. In all but one cases analyzed, the VH genes were unmutated. The FISH and HR-CGH analyses showed frequent occurrence of trisomy 12, del(11)(q23), del(17)(p13) and genetic imbalances, but recurrent genetic lesion characteristic for CLL/PL was not found. The follow-up HR-CGH analysis of two cases showed that increase of prolymphocytes in the course of CLL or CLL/PL are associated with clonal evolution and selection of the tumour clone. In conclusion, this study suggests that CLL/PL is a relatively homogeneous disease regarding VH gene mutation, but heterogeneous regarding genetic lesions. The heterogeneity and high number of genomic imbalances found in CLL/PL suggest that a genome-wide instability of the neoplastic cells may play a role in the development of the disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hon.812 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.
Cancers (Basel)
October 2024
Hematology Unit, Ospedale Guglielmo da Saliceto, Azienda USL di Piacenza, 29100 Piacenza, Italy.
Chronic Lymphocytic Leukemia (CLL) is the most frequent type of leukemia in Western countries. In recent years, there have been important advances in the knowledge of molecular alterations that underlie the disease's pathogenesis. Very heterogeneous prognostic subgroups have been identified by the mutational status of immunoglobulin heavy variable genes (), FISH analysis and molecular evaluation of mutations.
View Article and Find Full Text PDFMicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.
Noncoding RNA
August 2024
Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
A "watch and wait" strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however, prognostic models incorporating biomarkers have shown to be useful to predict treatment requirement. In our prospective O-CLL1 study including 224 patients, we investigated the predictive role of 513 microRNAs (miRNAs) on time to first treatment (TTFT). In the context of this study, six well-established variables (i.
View Article and Find Full Text PDFIdentification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE.
Blood Adv
January 2025
Department of Hematology, Centre Henri Becquerel, Rouen, France.
Article Synopsis
- * Out of 75 patients with successful BCR expression, a significant majority had mutated immunoglobulin heavy chains (IgVH), and a subgroup of 12 patients showed a highly dominant BCR clone associated with worse clinical outcomes.
- * The results indicated that high clonal dominance correlates with reduced BCR diversity and increased expression of specific genes, leading to poorer progression-free survival (PFS) and overall survival (OS) rates, corroborated by an independent patient cohort analysis.
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
Br J Haematol
August 2024
Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France.
Article Synopsis
- The study explored how genetic changes impact prognosis in chronic lymphocytic leukemia (CLL) patients, focusing on the role of immunoglobulin heavy variable (IGHV) status.
- In 536 patients undergoing first-line therapies, specific genetic abnormalities like unmutated IGHV and complex karyotype were linked to shorter progression-free survival (PFS).
- The effects of these genetic factors varied based on whether patients had mutated (M-IGHV) or unmutated (UM-IGHV) IGHV, emphasizing the importance of considering IGHV status in prognosis assessments for CLL.
CD20+ T cells in monoclonal B cell lymphocytosis and chronic lymphocytic leukemia: frequency, phenotype and association with disease progression.
Front Oncol
March 2024
Flow Cytometry Unit, Department of Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Introduction: In monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL), the expansion of malignant B cells disrupts the normal homeostasis and interactions between B cells and T cells, leading to immune dysregulation. CD20+ T cells are a subpopulation of T cells that appear to be involved in autoimmune diseases and cancer.
Methods: Here, we quantified and phenotypically characterized CD20+ T cells from MBL subjects and CLL patients using flow cytometry and correlated our findings with the B-cell receptor mutational status and other features of the disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!